Frontiers in Oncology | 卷:10 |
Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia | |
Zachary French1  Joanne Filicko-O'Hara2  Usama Gergis2  Lindsay Wilde2  Gina Keiffer2  Adam F. Binder2  | |
[1] Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, United States; | |
[2] Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States; | |
关键词: COVID-19; SARS-CoV-2; tocilizumab; cytokine storm; aplastic anemia; | |
DOI : 10.3389/fonc.2020.562625 | |
来源: DOAJ |
【 摘 要 】
While cytokine storm develops in a minority of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, novel treatment approaches are desperately needed for those in whom it does. Tocilizumab, an interleukin-6 receptor antibody, has been utilized for the treatment of cytokine storm in a number of severe inflammatory conditions, including in patients with severe coronavirus disease 2019 (COVID-19). Here, we present the first published case utilizing this therapy in a patient with underlying immunodeficiency. Our patient with aplastic anemia developed cytokine storm due to COVID-19 manifested by fever, severe hypoxia, pulmonary infiltrates, and elevated inflammatory markers. Following treatment with tocilizumab, cytokine storm resolved, and the patient was ultimately safely discharged from the hospital.
【 授权许可】
Unknown